Market Access/ News/ News AZ, MSD’s Koselugo is first EU therapy for neurofibromatosis Phil Taylor AstraZeneca, EU, Koselugo, Merck & Co, Neurofibromatosis, regulatory approval, Selumetinib 0 Comment The European Commission has approved AstraZeneca and MSD’s Koselugo for a rare genetic condition that causes tumours to Share X AZ, MSD’s Koselugo is first EU therapy for neurofibromatosis https://pharmaphorum.com/news/az-msds-koselugo-is-first-eu-therapy-for-neurofibromatosis/